Table of Content



Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.2 Volume Price Analysis
1.7 List Of Secondary Sources
1.8 List Of Primary Sources
1.9 List Of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.2.1 Product
2.3 Competitive Insights
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rapid Technological Advancements
3.2.1.2 Increasing Initiatives By Social Organizations To Improve Access To Condoms
3.2.1.3 Rising Publicly Funded Family Planning Services
3.2.2 Market Restraint Analysis
3.2.2.1 Increasing Geriatric Population And Rising Prevalance Of Infertility
3.2.2.2 Adverse Effects Associated With Use Of Contraceptive Drugs And Devices
3.3 Business Environment Analysis Tools
3.3.1 Pestle Analysis
3.3.1.1 Political & Legal Landscape
3.3.1.2 Economic & Social Landscape
3.3.1.3 Technological Landscape
3.3.2 Porter’s Five Forces Analysis
3.3.2.1 Competitive Rivalry - High
3.3.2.2 Bargaining Power Of Suppliers - Moderate
3.3.2.3 Bargaining Power Of Buyers - Moderate
3.3.2.4 Threat Of New Entrants - High
3.3.2.5 Threat Of Substitutes - Moderate
3.4 Penetration & Growth Prospect Mapping
3.4.1 Analysis
3.5 Pipeline Analysis
3.6 Regulatory & Reimbursement Framework
3.6.1 Regulatory Scenario
3.6.2 Reimbursement Framework
3.7 Impact Of COVID - 19: Qualitative Analysis
Chapter 4 U.S. Contraceptive Market: Product Analysis
4.1 U.S. Contraceptive Market Share Analysis, 2019 & 2027
4.2 U.S. Contraceptive Product Market: Segment Dashboard
4.3 Market Size & Forecasts And Trend Analysis, 2016 To 2027 For The Product Segment
4.3.1 Pills
4.3.1.1 Pills Market, 2016 - 2027 (USD Million)
4.3.2 Intrauterine Device (IUD)
4.3.2.1 Intrauterine Device Market, 2016 - 2027 (USD Million)
4.3.2.2 Hormonal IUD
4.3.2.2.1 Hormonal IUD Market, 2016 - 2027 (USD Million)
4.3.2.3 Nonhormonal IUD
4.3.2.3.1 Nonhormonal IUD Market, 2016 - 2027 (USD Million)
4.3.3 Condoms
4.3.3.1 Condoms Market, 2016 - 2027 (USD Million)
4.3.4 Vaginal Ring
4.3.4.1 Vaginal Ring Market, 2016 - 2027 (USD Million)
4.3.5 Subdermal Implants
4.3.5.1 Subdermal Implants Market, 2016 - 2027 (USD Million)
4.3.6 Injectable
4.3.6.1 Injectable Market, 2016 - 2027 (USD Million)
4.3.7 Others
4.3.7.1 Others Market, 2016 - 2027 (USD Million)
Chapter 5 U.S. Long Acting Reversible Contraception (LARC) Market
5.1 Penetration Analysis
Chapter 6 Competitive Analysis
6.1 Recent Developments & Impact Analysis, By Key Market Participants
6.2 Strategic Framework/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
6.3 Major Deals & Strategic Alliances Analysis
6.3.1 Mergers & Acquisitions And Joint Ventures
6.3.2 Licensing & Partnership And Technology Collaborations
6.4 Vendor Landscape
6.4.1 List Of Players In U.S. Contraceptive Market
6.4.2 Company Market Position Analysis (Market Presence, Employee Strength, Product Portfolio, Strategic Initiatives)
6.5 Company Profiles
6.5.1 Church & Dwight Co., Inc.
6.5.1.1 Company Overview
6.5.1.2 Financial Performance
6.5.1.3 Product Benchmarking
6.5.1.4 Strategic Initiatives
6.5.1.5 Swot Analysis
6.5.2 Reckitt Benckiser Group Plc
6.5.2.1 Company Overview
6.5.2.2 Financial Performance
6.5.2.3 Product Benchmarking
6.5.2.4 Strategic Initiatives
6.5.2.5 Swot Analysis
6.5.3 Veru, Inc.
6.5.3.1 Company Overview
6.5.3.2 Financial Performance
6.5.3.3 Product Benchmarking
6.5.3.4 Strategic Initiatives
6.5.3.5 Swot Analysis
6.5.4 Merck & Co., Inc.
6.5.4.1 Company Overview
6.5.4.2 Financial Performance
6.5.4.3 Product Benchmarking
6.5.4.4 Strategic Initiative
6.5.4.5 Swot Analysis
6.5.5 Pfizer, Inc.
6.5.5.1 Company Overview
6.5.5.2 Financial Performance
6.5.5.3 Product Benchmarking
6.5.5.4 Strategic Initiatives
6.5.5.5 Swot Analysis
6.5.6 Teva Pharmaceutical Industries Ltd.
6.5.6.1 Company Overview
6.5.6.2 Financial Performance
6.5.6.3 Strategic Initiatives
6.5.6.4 Swot Analysis
6.5.7 The Cooper Companies, Inc.
6.5.7.1 Company Overview
6.5.7.2 Financial Performance
6.5.7.3 Product Benchmarking
6.5.7.4 Strategic Initiative
6.5.7.5 Swot Analysis
6.5.8 Mayer Laboratories, Inc.
6.5.8.1 Company Overview
6.5.8.2 Product Benchmarking
6.5.9 Agile Therapeutics
6.5.9.1 Company Overview
6.5.9.2 Financial Performance
6.5.9.3 Product Benchmarking
6.5.9.4 Strategic Initiatives
6.5.9.5 Swot Analysis
6.5.10 TherapeuticsMD, Inc.
6.5.10.1 Company Overview
6.5.10.2 Financial Performance
6.5.10.3 Product Benchmarking
6.5.10.4 Strategic Initiative
6.5.10.5 Swot Analysis
6.5.11 Allergan
6.5.11.1 Company Overview
6.5.11.2 Financial Performance
6.5.11.3 Product Benchmarking
6.5.11.4 Strategic Initiatives
6.5.11.5 Swot Analysis
6.5.12 Bayer Ag
6.5.12.1 Company Overview
6.5.12.2 Financial Performance
6.5.12.3 Product Benchmarking
6.5.12.4 Strategic Initiatives
6.5.12.5 Swot Analysis
6.5.13 Afaxys, Inc.
6.5.13.1 Company Overview
6.5.13.2 Product Benchmarking
6.5.13.3 Strategic Initiatives
6.5.13.4 Swot Analysis
6.5.14 Mithra Pharmaceuticals
6.5.14.1 Company Overview
6.5.14.2 Financial Performance
6.5.14.3 Product Benchmarking
6.5.14.4 Strategic Initiatives
6.5.14.5 Swot Analysis
6.5.15 Blairex Laboratories, Inc.
6.5.15.1 Company Overview
6.5.15.2 Financial Performance
6.5.15.3 Product Benchmarking
6.5.16 Sebela Pharmaceuticals
6.5.16.1 Company Overview
6.5.16.2 Financial Performance
6.5.16.3 Product Benchmarking
6.5.16.4 Strategic Initiatives
6.5.17 Mona Lisa
6.5.17.1 Company Overview
6.5.17.2 Product Benchmarking
6.5.18 Pregna International Ltd.
6.5.18.1 Company Overview
6.5.18.2 Financial Performance
6.5.18.3 Product Benchmarking
6.5.19 Prosan International B.V.
6.5.19.1 Company Overview
6.5.19.2 Financial Performance
6.5.19.3 Product Benchmarking
6.5.20 SMB Corporation Of India
6.5.20.1 Company Overview
6.5.20.2 Financial Performance
6.5.20.3 Product Benchmarking
6.5.21 Abbvie
6.5.21.1 Company Overview
6.5.21.2 Financial Performance
6.5.21.3 Product Benchmarking
6.5.21.4 Strategic Initiatives
6.5.21.5 Swot Analysis
6.5.22 MELBEA Innovations Ltd.
6.5.22.1 Company Overview
6.5.22.2 Product Benchmarking
6.5.23 DKT International
6.5.23.1 Company Overview
6.5.23.2 Financial Performance
6.5.23.3 Product Benchmarking
6.5.23.4 Strategic Initiatives
6.5.23.5 Swot Analysis
6.5.24 OCON Healthcare
6.5.24.1 Company Overview
6.5.24.2 Product Benchmarking
Chapter 7 Recommendations
7.1 KOL Comments
7.2 Recommendations
Chapter 8 Research Methodology & Scope
8.1 Market Definition
8.1.1 Product
8.2 Research Methodology
8.3 Information Procurement
8.3.1 Purchased Database
8.3.2 GVR’s Internal Database
8.3.3 Secondary Sources
8.3.4 Primary Research
8.4 Information Or Data Analysis
8.4.1 Data Analysis Models
8.5 Market Formulation & Validation
8.6 Model Details
8.6.1 Commodity Flow Analysis
8.6.2 Variable Analysis
8.7 List Of Secondary Sources
8.8 List Of Primary Sources
8.9 List Of Abbreviations
Chapter 9 Report FAQs
9.1 How Do I Trust Your Report Quality/Data Accuracy?
9.2 My Research Requirement Is Very Specific; Can I Customize This Report?
9.3 I Have A Pre-Defined Budget. Can I Buy Chapters/Sections Of This Report?
9.4 How Do You Arrive At These Market Numbers?
9.5 Who Are Your Clients?
9.6 how Will I Receive This Report?
Chapter 10 Appendix
Chapter 11 Compass - Cloud Based Report Delivery Platform
Chapter 12 Related Reports



List of Tables



TABLE 1 List of Secondary Sources
TABLE 2 List of Abbreviation
TABLE 3 U.S. Contraceptive Market, By Product, 2016 - 2027 (USD Million)